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Introduction
Hepatocellular carcinoma (HCC) is the third most 
deadly neoplasm in the world. It is considered a rare 
primary malignancy in North America and Europe, 
in contrast to Asia and Africa.1 Statistics of the World 
Health Organization (WHO) report over 600,000 
HCC-related deaths per year worldwide. In Belgium 
the annual incidence is low. Of the whole popula-
tion, 484 new cases were registered by the National 
Cancer Registry for 2006, but this number seems 
to be increasing continuously. The most common 
aetiology of HCC is chronic hepatic cirrhosis relat-
ed to alcohol consumption, exposure to aflatoxin, 
metabolic or autoimmune diseases and hepatitis B 
or C viral infection. Theoretically, secondary liver 
metastases can occur with any invasive neoplasm, 
but the most frequently occurring primary tumours 
are colorectal, breast, stomach, pancreas and lung 
tumours.
The preferred treatment for HCC is surgery but the 
prognosis of the disease is poor, as at most 20% of 
the patients is eligible for surgical resection or liver 
transplantation. The 5-year survival after total exci-
sion or transplantation is 12-55%.2 Surgical removal, 
if feasible, is considered standard treatment for liver 
metastases. This approach yields interesting results 
in selected patients, but the indication for surgery 
is limited by the number, the localisation and the 
dimension of the lesions, the actual state of the 
primary tumour and the severity of the underlying 
hepatic disease. 
Thus, there is room for non-surgical treatment 
modalities in the management of both primary and 
secondary liver malignancies. Modern, high preci-
sion radiotherapy techniques, able to administer a 
highly conformal radiation dose in a few fractions, 
have the potential to be as ablative as a surgical 
resection.3 After the recent launch of a Cyberknife® 
system, enabling stereotactic irradiation with 
unrivalled accuracy, the Department of Radiation 
Oncology of Liège University Hospital nowadays 
broadens the field of potential indications for 
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radiotherapy to encompass primary and secondary 
liver tumours. 
Management of the disease
In the management of HCC one of the most impor-
tant factors for therapeutic decision making is 
the severity of the underlying hepatic disease, and 
hence the remaining functional capacity of the liv-
er. To assess the prognosis of chronic liver disease 
the Child-Pugh classification system is used widely. 
Five clinical parameters are scored in this system: 
serum bilirubin, serum albumin, INR, severity of 
ascites and encephalopathy. For patients in Child-
Pugh class A and for some patients in class B, sur-
gical resection could be the preferred treatment if 
technically and clinically feasible. For unresectable 
tumours, and in Child-Plugh class C, the possibility 
of including the patient in an orthotopic liver trans-
plantation programme has to be evaluated. 
A detailed treatment decision tree has been pub-
lished by the Barcelona Clinic.4
For secondary liver metastases, surgeons consider 
resection as the preferred treatment whenever possible.
Nowadays, a large number of non-surgical treatment 
modalities is available. The indications for these 
techniques differ and the accessibility can vary from 
one institution to another. We intend to review non-
surgical treatment options and focus especially on 
highly conformal ablative radiotherapy.
Chemotherapy has a limited role to play in the treat-
ment of HCC, but in contrast, it is of major impor-
tance to the treatment of secondary malignancies 
in the liver. However, more recently a new drug for 
the treatment of primary hepatocellular carcinoma 
has been put forward: sorafenib (Raf kinase inhibi-
tor, vascular endothelial growth factor receptor 
(VEGFR) inhibitor and platelet-derived growth fac-
tor (PDGFR) inhibitor). 
Non-surgical local treatment modalities
A non-surgical treatment approach for HCC is con-
sidered in case of technical unresectability, as neoad-
juvant treatment before resection, or as therapeutic 
strategy before ortothopic liver transplantation. In 
the latter case the treatment is often called bridg-
ing therapy with the intention of decreasing or sta-
bilising the disease until a donor is found and the 
planned surgical intervention can be realised.
Percutaneous ethanol injection (PEI) is one of the 
non-surgical approaches based on the injection of 
95% alcohol into the tumour. Tumour size should 
not exceed 2 cm and the injections frequently have 
to be repeated. An alternative approach is radiofre-
quency ablation (RFA). This is a heat-based ablation, 
obtained through placement of the needle within 
the tumour, which should not exceed 3-5 cm, and 
which should not be close to a large vessel in order 
to ensure the ablative temperature is obtained.
Other alternatives are transarterial embolisation 
(TAE) with bland particles, and transarterial che-
moembolisation (TACE). For the latter technique a 
variety of choices in embolising material (polyvinyl 
alcohol, gelatine sponge) and chemotherapy agents 
(mitomycin, doxorubicin, cisplatin) is currently 
available. In theory, there is no limitation for this 
technique in terms of tumour size.
Other local treatment approaches to hepatic lesions 
include cryoablation, percutaneous laser ablation, 
microwave ablation and radioembolisation (radio-
active isotopes attached to embolising material: 
TheraSphere, SIR-Sphere). Very often, local treat-
ment modalities are combined sequentially or syn-
chronously.
Radiotherapy as local treatment
Liver neoplasms, whether primary or secondary, are 
not considered to be classical indications for radio-
therapy. This is mainly due to the tolerance of nor-
mal liver tissue to ionizing irradiation. However, as 
early as 1990, the University of Michigan reported 
their experience in irradiation of liver tumours with 
conformal 3D RT.5 In a phase II study, Mornex et al. 
in Lyon, France achieved 78% complete response 
with a dose of 66 Gy /2 Gy fractions in 27 patients 
with small (<5 cm) primary HCC.6
For conventional 3D-based radiotherapy regimens, 
low doses per fraction (1.5-1.8 Gy) are used, even-
tually resulting in 2 fractions a day. Using such 
hyperfractionated schedules, dose-escalation stud-
ies have been performed, illustrating a clear dose-
response relationship in case of HCC and meta-
static liver lesions.7-10 Optimal imaging for tumour 
delineation, high dose conformality and hence low 
doses on surrounding healthy tissue, and taking tar-
get motion linked to respiration into account, yields 
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the opportunity for hypofractionation. For this type 
of treatment schedule a limited number of fractions 
(typically 2-5), possibly a single fraction, are applied 
resulting in a much higher biological effect. The lat-
ter can be compared to surgical removal and hence 
is called ablative radiotherapy. These techniques are 
reported as stereotactic body radiotherapy (SBRT) 
and stereotactic radiosurgery. 
In these techniques a high number of usually non-
coplanar photon radiation beams are used making 
high conformality and steep dose gradient around 
the tumour possible, resulting in a decrease of the 
dose on surrounding normal tissue. 
There are 2 ways to administer such highly con-
formal treatments. Firstly, the conventional linear 
accelerator based SBRT with stereotactic body-frame 
to assure accurate immobilisation. This approach is 
not new; the Karolinska Institute in Sweden pub-
lished the first experience with abdominal stereo-
tactic treatments in 1994.11 Image guidance with 
respiratory gating in accelerator based SBRT is criti-
cal, as the liver and therefore the target lesion can 
move 2.5 cm in superior-inferior direction due to 
respiration.12-15 This technique is usually applied 
under abdominal compression to decrease the respi-
ratory related displacement of the diaphragm, and 
hence the liver. Motion due to breathing can also be 
compensated by gating or by active breathholding 
techniques. For the latter techniques the beam is 
continously switched on and off, obviously prolong-
ing the overall treatment time. The second approach 
involves a dedicated system such as the robotic fra-
meless Cyberknife© System. 
The 6 MV accelerator, mounted on a robotic arm, 
has 6 degrees of freedom in movement. It has the 
capacity of using hundreds of beam positions on a 
half-sphere surface around the patient. Implantation 
of small gold fiducials in the immediate surround-
ings of the target, especially in liver tumours, is a 
prerequisite for the X-ray near real-time tracking of 
the tumour. Using infrared (IR) light emitting diodes 
on the surface of the thorax and an IR detector, the 
system is able to follow the respiratory related dis-
placement of the target, and maintain continuous 
beam administration. This system can easily admin-
ister non-isocentric treatments in case of irregular 
tumour shapes.
Radiotherapy with heavy charged particles is another 
encouraging treatment option but cannot be con-
sidered routinely as yet. The team of Chiba reported 
87% 5-year local control rate in a study of 162 HCC 
patients treated with proton RT (median dose of 72 
Gy/4.5 Gy fractions).16 Proton therapy is characterized 
by precise energy deposition at a depth defined by the 
energy of the entrance beam (Bragg peak), while mini-
mizing entrance dose and eliminating dose behind the 
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Bragg peak. In this context, dealing with target motion 
becomes an essential and yet unresolved issue. Proton 
beam radiotherapy is not yet available in Belgium. 
Indications and limitations of sterotac-
tic liver irradiation
Stereotactic high precision radiotherapy in primary 
HCC can be the preferred treatment as bridging thera-
py to stabilize or decrease the lesion in patients waiting 
for liver transplantation. Some patients will be waiting 
as long as a year for surgery. It can even be considered 
as the principal local treatment option in cases where 
neither resection nor transplantation are feasible. 
In the treatment of hepatic oligometastases (1-3), 
the indication is even more well-founded according 
to the results of a recent phase I/II trial, reporting 
that SBRT can be as effective as surgical removal.3 Of 
course, for both primary and secondary liver lesions, 
radiotherapy can be combined with other non-surgi-
cal treatment options as well.
The size and the number of the lesions can be a 
contraindication for the RT treatment. In most stud-
ies, patients are eligible, provided they present 1-3 
lesions, with a maximum diameter of 5-6 cm. Care 
should be taken, when considering SBRT, that a cer-
tain volume of healthy liver tissue is spared. When 
performing dosimetric evaluation of SBRT prior to 
treatment, normal tissue complication probabil-
ity models (NTCP) can be used to predict the risk 
for surrounding normal tissue. In case of liver dis-
ease, gold markers should be implanted in order to 
allow tracking and to limit margins around the tar-
get volume. Because of the invasive nature of fidu-
cial placement coagulation dysfunction represents a 
contraindication (Child-Pugh C). Portal vein throm-
bosis however, is not a contraindication for SBRT, 
in contrast to other treatment options, such as PEI 
and TACE. Even centrally located tumours can be 
treated with SBRT although the vicinity of stomach 
and bowel close to the high dose region can be a 
technical problem.
Reported experiences in liver SBRT
A growing number of publications reveal the poten-
tial role of stereotactic RT in the treatment of prima-
ry liver tumours and liver metastases.9,17-28 Survival 
and local control rates and the dose-fractionation 
schedules are shown in Table 1 (page 10) and 2. 
Total dose and dose per fraction, and hence total 
number of fractions are different but generally, a 
hypofractionated schedule is used. A number of 
studies are designed to investigate dose escalation. 
In liver metastasis a stereotactic treatment of 60 Gy 
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in 3 fractions can be administered without dose-lim-
iting toxicity.3,26 If a single-fraction treatment is used, 
the dose administered can be as high as 26 Gy.
The 1-year and 2-years local control (LC) rates are 
very promising: 95% and 92% respectively for liver 
metastases and 94% and 82% respectively for mixed 
study population of HCC and metastases.3,23 In a 
study population with only primary HCC, 65% 
1-year LC has been achieved.18 When receiving the 
pathological report after orthotopic liver transplanta-
tion due to oligometastases, a complete pathological 
response as high as 42% has been reported.28 
Toxicity 
Most common acute toxicities of SBRT are chills, pain, 
fever, loss of appetite, nausea-vomiting, fatigue, gastri-
tis, oesophagitis, thrombocytopenia and deterioration 
in liver functions. Radiation-Induced Liver Disease 
(RILD) consisting of hepatomegaly, ascites and elevat-
ed liver enzymes, usually appears 30-60 days after RT. 
Late toxicities are gastrointestinal ulcer, non-traumatic 
rib fracture and definitive deterioration in liver func-
tions causing progression in Child-Pugh class. Toxicity 
data are presented in Table 1 (page 10) and 2.
Even now, some data are available on dose-volume 
constraints especially for hepatic function. Dawson 
et al. suggest a TD 5/5 (tolerance dose resulting 
in a normal tissue complication probability of 5% 
within 5 years after RT) of 31 Gy for the whole liver, 
47 Gy for 2/3 liver, 90 Gy for 1/3 liver.29 The same 
group suggests adapting the given dose individually, 
accepting a 10% toxicity level calculated by using 
the Lyman-NTCP model. 
Other constraints reported in the literature, show 
that at least 700/800 ml of the normal liver should 
receive a total dose <15 Gy/18 Gy in order to pre-
serve hepatic function.22,26
In case of liver targets, gold fiducials need to be 
implanted in order to be able to track. This obvi-
ously harbours the risk of an invasive procedure, but 
also the possibility of tumour cell seeding along the 
needle track. This risk cannot be neglected as shown 
by reported incidence of seeding (0-12.5%) in other 
techniques, such as RFA.30 
Conclusion
Stereotactic body radiotherapy allows administer-
ing ablative doses on liver lesions while sparing the 
surrounding healthy tissue and minimising the risk 
of complications. Different groups report high local 
control rates with relatively low incidence of grade 
3 or higher toxicity. Although fiducial implanta-
tion is required if one intends to track the lesion 
in real-time, the robotic radiosurgery approach can 
be labelled as a non-invasive and yet ablative pro-
cedure. According to published data, local control 
and survival are at least comparable to other avail-
able treatment techniques, even to surgery. Safety 
of the procedure has been demonstrated both for 
oligometastases in the liver and for HCC. For the lat-
ter disease, SBRT can be used as a bridging therapy 
before liver transplantation or exclusively, if patients 
are not eligible for surgery. Nowadays, the total dose 
and the number of fractions are not settled and 
SBRT still has to be compared to surgery in operable 
patients in randomized trials. These trials should 
ideally evaluate the influence on the quality of life 
and the total cost of stereotactic radiotherapy as 
well. However, it is a safe and effective treatment in 
selected patients, if surgery is not an option.    
Key messages for clinical practice
1. High precision modern stereotactic radiotherapy is a safe, minimally invasive 
treatment option for liver lesions. 
2. High local control rates can be achieved.
3. Optimal total dose and number of fracions should be further investigated in 
clinical trials.
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